Table 1.
Patients' characteristics
| No. of patients | 139 |
| Mean age: years (range) | 32.5 (15–56) |
| Median follow-up period: months (range) | 75.5 (2.4–304) |
| Primary site (n) | |
| Testis (right/left) | 135 (68/67) (97.1%) |
| Retroperitoneal | 3 (2.2%) |
| Mediastinum | 1 (0.7%) |
| Histology (n) | |
| Seminoma | 53 (38.1%) |
| Clinical stage | |
| I | 41 |
| II | 9 |
| III | 3 |
| Non-seminomatous germ cell tumor | 86 (61.9%) |
| Clinical stage | |
| I | 30 |
| II | 20 |
| III | 36 |
| Treatment added to orchiectomy (n) | |
| None | 25 |
| Radiation only | 38 |
| Chemotherapy only | 16 |
| Radiation + chemotherapy | 2 |
| Chemotherapy + surgical resection of metastatic site | 54 |
| RPLND only | 4 |
| Chemotherapy regimen (n) | |
| PVB | 27 |
| BEP/EP | 63 |
| VIP | 19 |
| VeIP | 2 |
| High-dose ICE + autologous HCT | 11 |
| TIP/TIN | 6 |
| Irinotecan + nedaplatin | 5 |
RPLND, retroperitoneal lymph node dissection; PVB, cisplatin + vinblastine + bleomycin; BEP, bleomycin + etoposide + cisplatin; VIP, etoposide + ifosphamide + cisplatin; VeIP, vinblastine + ifosphamide + cisplatin; ICE, ifosphamide + carboplatin + etoposide; HCT, hematopoietic cell transplantation; TIP, paclitaxel + ifosphamide + cisplatin; TIN, paclitaxel + ifosphamide + nedaplatin.